ORMP — Oramed Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $94.77m
- -$48.07m
- 57
- 45
- 86
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.65 | ||
| Price to Tang. Book | 0.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.54% | ||
| Return on Equity | -12.29% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.71 | 2.7 | 2.7 | 1.34 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Directors
- Kevin Rakin NEC (61)
- Nadav Kidron CEO (47)
- David Silberman CFO (38)
- Joshua Hexter COO (51)
- Miriam Kidron CSO (81)
- Netanel Derovan GCN
- Michael Rabinowitz OTH (56)
- Aviad Friedman IND (50)
- Arie Mayer IND (66)
- Leonard Sank IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 10th, 2011
- Public Since
- April 1st, 2002
- No. of Shareholders
- 40
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 40,850,455
- Address
- 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, 10036
- Web
- https://oramed.com/
- Phone
- +1 6468441164
- Auditors
- Kesselman & Kesselman
Upcoming Events for ORMP
Oramed Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Oramed Pharmaceuticals Inc Earnings Release
Similar to ORMP
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Oramed Pharmaceuticals share price?
As of Today at 22:29 UTC, shares in Oramed Pharmaceuticals are trading at $2.32. This share price information is delayed by 15 minutes.
How has the Oramed Pharmaceuticals share price performed this year?
Shares in Oramed Pharmaceuticals last closed at $2.32 and the price had moved by -0.85% over the past 365 days. In terms of relative price strength the Oramed Pharmaceuticals share price has underperformed the S&P500 Index by -10.6% over the past year.
What are the analyst and broker recommendations for Oramed Pharmaceuticals?
The overall consensus recommendation for Oramed Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Oramed Pharmaceuticals dividend yield?
Oramed Pharmaceuticals does not currently pay a dividend.
Does Oramed Pharmaceuticals pay a dividend?
Oramed Pharmaceuticals does not currently pay a dividend.
When does Oramed Pharmaceuticals next pay dividends?
Oramed Pharmaceuticals does not currently pay a dividend.
How do I buy Oramed Pharmaceuticals shares?
To buy shares in Oramed Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oramed Pharmaceuticals?
As of the previous close price of $2.32, shares in Oramed Pharmaceuticals had a market capitalisation of $94.77m.
Where are Oramed Pharmaceuticals shares listed?
Here are the trading details for Oramed Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ORMP
What kind of share is Oramed Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Oramed Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oramed Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Oramed Pharmaceuticals is $3.25. That is 40.09% above the last closing price of $2.32.
Analysts covering Oramed Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.07 for the next financial year.
Find out moreWhat is the trend in the Oramed Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oramed Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +0.46%.
As of the last closing price of $2.32, shares in Oramed Pharmaceuticals were trading -1.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oramed Pharmaceuticals PE Ratio?
The Oramed Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oramed Pharmaceuticals?
Oramed Pharmaceuticals' management team is headed by:
- Kevin Rakin - NEC
- Nadav Kidron - CEO
- David Silberman - CFO
- Joshua Hexter - COO
- Miriam Kidron - CSO
- Netanel Derovan - GCN
- Michael Rabinowitz - OTH
- Aviad Friedman - IND
- Arie Mayer - IND
- Leonard Sank - IND